Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lepodisiran in Renal Impairment
NCT05841277Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of lepodisiran in elevated lipoprotein(a) (Lp(a)) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area under the concentration versus time curve from time zero to last time point, Area under the concentration versus time curve from time zero to infinity and 1 more. Started Apr 2023; status: completed.
02
Drugs
lepodisiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05841277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841277.